- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 11/12 - Mucolytics
Patent holdings for IPC class A61P 11/12
Total number of patents in this class: 240
10-year publication summary
|
6
|
7
|
17
|
14
|
14
|
19
|
12
|
10
|
9
|
14
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| The Regents of the University of California | 20153 |
9 |
| Translate bio, Inc. | 416 |
8 |
| Enterprise Therapeutics Limited | 19 |
8 |
| Vertex Pharmaceuticals Incorporated | 1627 |
6 |
| Parion Sciences, Inc. | 59 |
5 |
| University College Dublin, National University of Ireland, Dublin | 361 |
5 |
| Novartis AG | 10707 |
4 |
| Boehringer Ingelheim International GmbH | 4644 |
4 |
| Galapagos NV | 274 |
4 |
| Universite de Poitiers | 188 |
4 |
| The University of North Carolina at Chapel Hill | 2059 |
4 |
| Know bio, LLC | 75 |
4 |
| Centre National de La Recherche Scientifique | 10595 |
3 |
| AbbVie S.á.r.l. | 27 |
3 |
| Algipharma AS | 42 |
3 |
| Discoverybiomed, Inc. | 15 |
3 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3369 |
3 |
| OrPro Therapeutics, Inc. | 10 |
3 |
| Shenzhen HighTide Biopharmaceutical, Ltd. | 57 |
3 |
| University College Dublin | 9 |
3 |
| Other owners | 151 |